Iron Sucrose interactions
Full monograph for Iron SucroseCheck it against another medicine
Medicines
59 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Erdafitinib | Major | Others | Coadministration with agents that can alter serum phosphate levels may affect the initial dosage determination of erdafitinib. The mechanism appears to be… | 1 sources — open the full entry |
| Alendronic acid | Moderate | Absorption | INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of bisphosphonates. The proposed mechanism is chelation of… | 6 sources — open the full entry |
| Alendronic Acid + Vitamin D3 | Moderate | Absorption | INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of bisphosphonates. The proposed mechanism is chelation of…2 documented mechanisms | 7 sources — open the full entry |
| Algae Calcium + Vitamin D3 | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Amlodipine Besilate + Benazepril Hydrochloride | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Beclomethasone Dipropionate + Chloramphenicol + Clotrimazole + Lidocaine | Moderate | Antagonism | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12… | 3 sources — open the full entry |
| Beta carotene + Vitamin C + Vitamin E | Moderate | Antagonism | Limited data suggest that vitamin E may diminish the therapeutic response to iron therapy in patients with iron deficiency anemia. | 2 sources — open the full entry |
| Calcium + Vitamin D3 + Multimineral | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C + Vitamin D3 | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 + Multiminerals | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Calcium Phosphate [Milk source] + Vitamin D3 | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Captopril | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Carbonyl Iron + Folic Acid | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Carbonyl Iron + Folic Acid + Zinc Sulfate + Vitamin B Complex + Vitamin C | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Chloramphenicol (Oral) | Moderate | Antagonism | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12… | 3 sources — open the full entry |
| Chloramphenicol + Lidocaine Hydrochloride | Moderate | Antagonism | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12… | 3 sources — open the full entry |
| Cholecalciferol [Vitamin D3] | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Conventional Calcium + Vitamin D3 | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Coral Calcium + Vitamin D3 | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Moderate | Antagonism | Chloramphenicol can cause bone marrow depression and inhibit red blood cell maturation, which may interfere with the therapeutic effects of iron or vitamin B12… | 3 sources — open the full entry |
| Doxercalciferol | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Doxycycline Hydrochloride | Moderate | Absorption | INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of tetracyclines. The proposed mechanism is chelation of… | 12 sources — open the full entry |
| Eggshell Calcium + Vitamin D3 | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Eggshell Calcium + Vitamin D3 + 19 Vitamin & Minerals | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Enalapril Maleate | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Ethinyl Estradiol + Levonorgestrel + Ferrous Fumarate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Ferric Maltol | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Ferrous Fumarate + Folic acid | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Ibandronic Acid | Moderate | Absorption | INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of bisphosphonates. The proposed mechanism is chelation of… | 6 sources — open the full entry |
| Ibandronic Acid + Algae Calcium + Vitamin D3 | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption…2 documented mechanisms | 7 sources — open the full entry |
| Ibandronic Acid + Coral Calcium + Vitamin D3 | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption…2 documented mechanisms | 7 sources — open the full entry |
| Iron + Folic Acid + Vitamin A + Vitamin C + Zinc | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Iron + Folic acid + Vitamin B complex + Vitamin C | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Iron + Folic Acid + Vitamin B Complex + Vitamine C + Zinc Sulfate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Iron Polymaltose Complex | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Iron Polymaltose Complex + Folic Acid + Zinc + Vitamin B-Complex | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Iron Polymaltose Complex + Folic Acid + Zinc Sulfate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Iron Polymaltose Complex + Vitamin B Complex + Zinc | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 5 sources — open the full entry |
| Levothyroxine Sodium | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of levothyroxine. The proposed mechanism involves nonspecific adsorption of… | 5 sources — open the full entry |
| Lisinopril | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Minocycline Hydrochloride | Moderate | Absorption | INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of tetracyclines. The proposed mechanism is chelation of… | 12 sources — open the full entry |
| Norgestrel + Ethinyl Estradiol + Ferrous Fumarate | Moderate | Absorption | Parenteral iron therapy may reduce the absorption of concomitantly administered oral iron preparations. | 4 sources — open the full entry |
| Oxytetracycline | Moderate | Absorption | INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of tetracyclines. The proposed mechanism is chelation of… | 12 sources — open the full entry |
| Oxytetracycline + Polymixin B Sulphate | Moderate | Absorption | INTERVAL: Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of tetracyclines. The proposed mechanism is chelation of… | 12 sources — open the full entry |
| Paricalcitol | Moderate | Absorption | Coadministration with sucroferric oxyhydroxide may reduce the oral bioavailability of vitamin D analogs. The proposed mechanism involves nonspecific adsorption… | 1 sources — open the full entry |
| Perindopril + Indapamide | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Perindopril Arginine | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
| Perindopril Arginine + Amlodipine | Moderate | Others | Limited data suggest that ACE inhibitors may increase the risk and/or severity of systemic adverse effects associated with parenteral administration of iron… | 8 sources — open the full entry |
Conditions
Conditions in which Iron Sucrose needs care, as documented in this source.
Hemochromatosis
MajorSucroferric oxyhydroxide contains iron and should be prescribed with caution in patients with a history of hemochromatosis or other diseases associated with iron accumulation. Iron homeostasis should be closely monitored, and the medication discontinued in patients who develop iron overload.
1 source
- "Product Information. Velphoro (sucroferric oxyhydroxide)." Fresenius Medical Care North America (2014):
Hemoglobinopathies
MajorThere is no excretory mechanism for iron. Iron will correct only hemoglobin abnormalities due to iron deficiency and should not be used to treat conditions such as thalassemia, hemosiderosis, hemochromatosis, normocytic anemia (unless iron deficiency exists), or in patients receiving blood transfusions. Clinical monitoring of erythropoietic function and ferritin levels is recommended.
2 sources
- "Product Information. Infed (iron dextran)." Schein Pharmaceuticals Inc
- "Product Information. Venofer (iron sucrose)." American Regent Laboratories Inc (2001):
Therapeutic duplication
Drug classes that overlap with Iron Sucrose, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.
iron preparations
The recommended maximum number of medicines in the 'iron preparations' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'iron preparations' category.
Example product in the source data (US market): Ferrous fumarate/iron polysaccharide
iron preparations
The recommended maximum number of medicines in the 'iron preparations' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'iron preparations' category.
Example product in the source data (US market): Hemocyte-f
iron preparations
The recommended maximum number of medicines in the 'iron preparations' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'iron preparations' category.
Example product in the source data (US market): Vitron-c